Form 4: ORAMED CFO Gabay Receives 95,889 RSU Grant

Oramed Pharmaceuticals Inc. Chief Financial Officer Avraham Gabay was granted 95,889 Restricted Stock Units, vesting quarterly starting April 1, 2026.

Summary

• Avraham Gabay, Chief Financial Officer of Oramed Pharmaceuticals Inc., was granted 95,889 Restricted Stock Units (RSUs).
• The RSUs represent the right to receive one share of common stock for each unit.
• These RSUs will vest ratably in 8 quarterly installments.
• The vesting period commences on April 1, 2026.
• Following this transaction, Gabay beneficially owns 745,145 shares directly.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this RSU grant as a moderately positive development, reflecting standard executive incentive practices and aligning management's interests with long-term shareholder value, without indicating any immediate operational changes.

Positives

• The grant of Restricted Stock Units aligns the Chief Financial Officer's interests with those of shareholders, promoting long-term value creation.
• Equity compensation is a standard practice for retaining key executives and incentivizing performance.

Negatives

• The issuance of new shares upon RSU vesting could lead to minor dilution for existing shareholders, though this is typical for equity compensation plans.

Future Outlook

The vesting schedule for the granted Restricted Stock Units indicates a commitment to executive retention and performance incentives extending through the next two years, with vesting commencing April 1, 2026.

Industry Context

StockSavvy.ai notes that granting Restricted Stock Units (RSUs) to key executives like the CFO is a common and effective compensation strategy in the pharmaceutical and biotechnology sectors. This practice helps align management's long-term interests with shareholder value, particularly in industries with long development cycles and significant R&D investments.

Comparison to Industry Standards

• The RSU grant to the CFO is consistent with typical executive compensation structures observed in publicly traded pharmaceutical companies, which often include a significant equity component to incentivize long-term performance and retention.
• Companies like Pfizer, Johnson & Johnson, and Merck frequently utilize similar RSU programs for their senior leadership, tying a portion of compensation to future stock performance and continued service.

Related Party Transactions

• The grant of 95,889 Restricted Stock Units to Avraham Gabay, the Chief Financial Officer, constitutes a related party transaction as it involves an executive officer of the company.

Stakeholder Impact

• Shareholders: The RSU grant aims to align the CFO's interests with shareholders, potentially leading to improved long-term performance, though it introduces minor potential for future share dilution upon vesting.
• Employees: This transaction reinforces the company's commitment to executive retention and performance-based compensation, which can positively influence overall employee morale and incentive structures.

Next Steps

• The 95,889 Restricted Stock Units will vest ratably in 8 quarterly installments.
• The first vesting installment is scheduled for April 1, 2026.

Key Dates

Recommendation

This Form 4 filing reports a routine equity grant to a key executive, which is a standard practice for executive compensation and retention. It does not provide new information that would fundamentally alter the investment thesis for Oramed Pharmaceuticals Inc., thus a 'hold' recommendation is appropriate as it maintains the status quo without presenting new catalysts for significant upside or downside.

Keywords

Oramed Pharmaceuticals, ORMP, Avraham Gabay, CFO, Restricted Stock Units, RSU, Equity Compensation, Insider Transaction, Form 4, Executive Compensation